Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The experimental ...
Pfizer said its experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial. Patients with the ...
Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...
A Remote Symptom Monitoring Tool As Part of Ambulatory Cancer Surgery Recovery: A Qualitative Analysis of Patient Experience This was a preplanned secondary analysis of a survey investigating ...
Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...
A new phase 2b/3 trial was approved to study of S-pindolol benzoate to treat cachexia, a wasting disease associated with cancer. The Food and Drug Administration (FDA) OKed phase 2b/3 trials to ...
"Cancer-related cachexia and sarcopenia occur in hematologic malignancies, not just gastrointestinal carcinomas and head and neck cancers. Their presence affects all aspects of diagnosis and treatment ...
When new data for anamorelin were presented at a large European meeting in 2014, oncology experts enthusiastically welcomed them, and hopes were raised that there may at last be a drug for cancer ...
Pfizer researchers say they are developing a drug that might counteract a condition that leads to the death of cancer patients within a year of its diagnosis. Photo by Stephanie Lecocq/EPA-EFE Sept.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results